This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Mataveli F, Calabró A, Mendes W, Vianna D, Dorlhiac-Llacer P, Bigni R, Hungria V.Cost-effectiveness of imatinib versus interferon-alpha in the treatment of patients newly diagnosed with chronic myeloid leukemia, under the Brazilian Public Healthcare System perspective. Blood 108: 946, No. 11, Part 1, Nov 2006
About this article
Cite this article
Imatinib considered cost-effective CML treatment in Brazil. Pharmacoecon. Outcomes News 520, 6 (2007). https://doi.org/10.2165/00151234-200705200-00016
- Cost Effectiveness
- Chronic Myeloid Leukaemia
- System Perspective